These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2007-000394-36 A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND... 2008-09-30 due-trials
Reported results 2014-005192-89 Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD) 2018-10-31 due-trials
Exempt, with results 2015-002057-35 A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose administr... 2017-10-05 not-yet-due
Trial is outside EEC, and reported results 2017-000320-10 A Phase III, Randomized, Double-Blind, Dose-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit S... bad-data
Trial is outside EEC, and reported results 2017-000406-38 A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥ 28 Weeks to ≤ 44 Weeks Gestational Age bad-data
Trial is outside EEC, and reported results 2017-000407-24 A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 months through <24 months bad-data
Trial is outside EEC, and reported results 2017-000408-71 A Phase II/Ill, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages 28 Weeks to < 36 Weeks Gestational Age bad-data

Related organisations

Over time organisations can merge, or split.

We think Hospira, Inc. is now effectively part of Pfizer.